快验保 MED 深 沪
已收盘 08-07 16:00:00 美东时间
12.62
+0.500
+4.13%
华盛通- 最 高12.84
- 今 开12.23
- 成交量 14.05万股
- 最 低 12.185
- 昨 收 12.12
- 总市值 1.41亿
- 52周最高 14.67
- 市盈率 静 --
- 换手率 1.26%
- 52周最低 9.22
- 委 比 0.00%
- 总股本 1118.07万
- 历史最高 321.22
- 量 比 0.36
- 振 幅 5.40%
- 历史最低 -17.07
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 绩优股齐升！Palantir大涨逾29%，Q2营收强劲增长并上调全年指引；Wayfair飙升30%，Corvex涨逾27%
绩优股齐升！Palantir大涨逾29%，Q2营收暴增93%并上调全年指引；Wayfair飙升30%，Q2业绩全面超预期；Corvex涨逾27%，斩获AI巨头Blackwell供应协议>>
08-05 19:24
11 Consumer Staples Stocks Moving In Monday's After-Market Session
Gainers Medifast (NYSE:MED) stock increased by 10.7% to $10.78 during Monday's after-market session. The market value of their outstanding shares is at $108.0 million. The company's, Q2 earnings came out today. Andersons (NASDAQ:ANDE) stock moved upwards by 10.22% to $77.0. The company's market cap ...
08-04 05:05
Medifast Q2 Adj. EPS $(0.28) Beats $(0.65) Estimate, Sales $76.384M Beat $72.700M Estimate
Medifast (NYSE:MED) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.65) by 56.92 percent. This is a 227.27 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $76.384 million which b...
08-04 04:09
Medifast Rebrands OPTAVIA as Trilivy Metabolic Health System
Medifast ( ($MED) ) has shared an update. On July 17, 2026, Medifast announced ...
07-17 20:58
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, making standard weight management programs ineffective. Women should focus on visceral fat and lean mass retention rather than scale weight. Sleep disruption, stress, and hormonal variability further complicate self-directed programs. OPTA VIA's clinically supported metabolic health programs target visceral fat while preserving lean mass, with stud...
06-11 11:00
What Science-Backed Subscription Health Programs Measure Differently
The weight loss and weight management market was valued at $31.07 billion in 2025 and is expected to surpass $45 billion by 2030. Many programs use terms like "clinically studied" or "science-backed" without specifying what was measured or how. Dual-energy X-ray absorptiometry (DXA) scanning, the clinical gold standard for body composition, provides more precise measurements than BMI or scale weight. OPTA VIA's study showed a 92.3% completion rat...
06-11 11:00
Medifast Announces New CEO and Leadership Transition
The latest announcement is out from Medifast ( ($MED) ). On May 19, 2026, Medif...
05-27 05:23
Medifast appoints Nicholas Johnson as CEO
Medifast (MED) has appointed Nicholas Johnson as chief executive officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as chairman of the board. Source: Pr...
05-27 04:17
Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
OPTAVIA's weight loss program emphasizes body composition, targeting visceral fat reduction and lean mass preservation for long-term metabolic health. Structured meal plans, high-quality protein, and coach support are key to achieving sustainable weight loss. Research shows participants in OPTAVIA's program lost 14% visceral fat and retained 98% lean mass in 16 weeks, outperforming independent weight loss attempts.
05-15 17:00
